From Almost Universally Fatal to Largely Treatable iTTP – American Society of Hematology
American Society of Hematology shared a post on LinkedIn about a recent article by Ahmet Emre Eşkazan, published in The Hematologist, adding:
“Immune-mediated thrombocytopenic purpura (iTTP) has undergone one of the most remarkable transformations in modern hematology.
Once considered almost universally fatal, it is now a largely treatable disease due to advances in therapeutic plasma exchange (TPE), immunosuppression, and targeted therapy.
Nevertheless, important challenges remain in early diagnosis, equitable access to treatment, relapse prevention, and long-term patient outcomes.”
Title: Small Vessels, Big Consequences: Immune-Mediated Thrombotic Thrombocytopenic Purpura
Authors: Ahmet Emre Eşkazan
Other posts featuring ASH on Hemostasis Today.
-
Oct 9, 2026, 12:22Eugene Fan: Bridging Therapeutic Breakthroughs and Equitable Thalassaemia Care
-
Oct 9, 2026, 12:14Brittany Busse: A New Focus on Iron Deficiency Before Anemia
-
Oct 9, 2026, 12:13Akshat Jain: A New Textbook Bringing Global Perspectives on Sickle Cell Disease
-
Oct 9, 2026, 12:03Heather Case: Bridging Awareness and Action in Women’s Hemophilia Care
-
Oct 9, 2026, 11:58Brandon Luu: Can Iron Deficiency Cause Fatigue Without Anemia?
-
Oct 9, 2026, 11:51Sumaiya Dickens: Marginal Zone B Cells in Transfusion Medicine and Hemophilia A Research
-
Oct 9, 2026, 11:44Ayyappan V Nair: PRP and Rehabilitation – Can It Help Athletes with Partial Rotator Cuff Tears?
-
Oct 9, 2026, 11:29Jigesha Dholakia: Supporting the Hemophilia Community Through the Unite Walk
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots